Carboplatin (Paraplatin)
Also known as cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) or Paraplatin-AQ.
General information
Class/mechanism: Platinum analog, alkylating-like, producing predominantly interstrand DNA crosslinks that are cell-cycle nonspecific.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Bladder cancer
- Bone cancer
- Breast cancer
- Cervical cancer
- Esophageal cancer
- Hodgkin lymphoma
- Melanoma
- Mesothelioma
- Non-small cell lung cancer
- Ovarian cancer
- Small cell lung cancer
- Testicular cancer
- Thymoma
- Unknown primary
- Uterine cancer
Patient drug information
- Carboplatin (Paraplatin) patient drug information (Chemocare)[4]
- Carboplatin (Paraplatin) patient drug information (UpToDate)[5]
References
Categories:
- Drug index
- Chemotherapy
- Platinum agents
- Alkylating agents
- Irritant chemotherapy
- Hodgkin lymphoma medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Cancer of unknown primary medications
- Cervical cancer medications
- Esophageal cancer medications
- Melanoma medications
- Mesothelioma medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Small cell lung cancer medications
- Testicular cancer medications
- Thymoma medications
- Uterine cancer medications